<DOC>
	<DOCNO>NCT02120807</DOCNO>
	<brief_summary>The purpose study test safety certolizumab give chemotherapy drug cisplatin pemetrexed . Cisplatin pemetrexed two chemotherapy drug use treatment lung cancer . The investigator want find effect , good and/or bad , certolizumab patient lung cancer .</brief_summary>
	<brief_title>Certolizumab Combination With Chemotherapy Patients With Stage IV Lung Adenocarcinomas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Previously untreated stage IV lung adenocarcinoma confirm MSKCC Age 18 year old Karnofsky Performance Status ≥ 70 Patients locally treat , stable , and/or asymptomatic brain metastasis eligible . Adequate bone marrow , liver renal function , specify : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ≥ 8 g/dL Platelets ≥ 100 x 109/L Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ( except patient document Gilbert 's Syndrome ) AST ALT ≤ 2.5 x ULN ≤ 5 x ULN liver metastases present Serum creatinine ≤ 1.5 x upper limit normal creatinine clearance ≥ 60ml/min patient creatinine level institutional normal . Negative PPD test For woman childbearing potential , negative pregnancy test within 14 day prior start treatment Men woman childbearing age must willing use effective contraception treatment least 3 month thereafter Presence least one site measurable disease define Response Evaluation Criteria Solid Tumors Archival tissue ( 10 Unstained Slides 5 micron section ) core biopsy perform receive within 30 day sign consent ability fresh core biopsy perform Biopsy cytology bone specimen Biopsy site must amenable rebiopsy end study Ability provide write , informed consent Hypersensitivity platinum agent Ongoing use investigational agent use investigational agent within last four week Prior use agent TNFalpha blockade History rheumatoid arthritis , inflammatory bowel disease , psoriatic arthritis Baseline hearing deficit ( CTCAE version 4.0 grade 2 high ) Ongoing bacterial , viral , antifungal infection require antimicrobial treatment exception thrush Active tuberculosis untreated , latent tuberculosis If patient sign , symptom , history suggestive active tuberculosis , evaluation infectious disease physician require active tuberculosis ruledout prior enrollment . Acute chronic Hepatitis B C infection Known HIV infection require antiretroviral medication AIDS Active herpes zoster infection Nonhealed infect skin ulcer History myocardial infarction unstable angina within past 12 month Ongoing use immunosuppressive medication , include oral steroid exclude topical steroid Women breastfeed Prior history malignancy exclusion localize prostate cancer , nonmelanomatous skin cancer , ductal carcinoma lobular carcinoma situ breast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Certolizumab</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>thoracic</keyword>
	<keyword>13-063</keyword>
</DOC>